報價延遲最少15分鐘:2024/04/28 22:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.24/-0.32
|
|
企業價值
190.46M
|
| 資產負債 |
|
每股賬面淨值
0.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/28 22:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |